Results 221 to 230 of about 6,936,275 (299)

Mammalian Queuosine tRNA Modification Impacts Translation to Enhance Cell Proliferation and MHC-II Expression. [PDF]

open access: yesJ Mol Biol
Zbihley ONP   +7 more
europepmc   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

open access: yesArthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen   +10 more
wiley   +1 more source

The Role of MHC-II Diversity over Enclosure Design in Gut Microbiota Structuring of Captive Bengal Slow Lorises. [PDF]

open access: yesBiology (Basel)
Jiang R   +11 more
europepmc   +1 more source

Type I Interferon Drives Dysfunction of a Distinct CD8+ HLA‐DRB1+ T Cell Subset in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long   +3 more
wiley   +1 more source

3D genome contributes to MHC-II neoantigen prediction. [PDF]

open access: yesBMC Genomics
Feng M   +9 more
europepmc   +1 more source

Single‐Cell RNA Sequencing of Peripheral Blood Defines Two Immunologic Subtypes of Sjögren's Disease Distinguished by Anti‐SSA Antibodies and Aberrant B Cell Populations

open access: yesArthritis &Rheumatology, EarlyView.
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski   +15 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu   +3 more
wiley   +1 more source

Dual‐targeted nanomedicine delivering doxorubicin and nitric oxide for tumor immunomodulation and synergistic therapy

open access: yesBMEMat, EarlyView.
The mechanism of HA‐DS@PLGA nanoparticles co‐delivering DOX and SNAP (an NO donor) to suppress tumor growth, remodel the tumor microenvironment, and enhance antitumor immune responses for effective combinatorial cancer therapy. Abstract Cancer therapeutic efficacy is significantly influenced by tumor immunosuppressive environment possibly induced by ...
Xingzhou Peng   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy